Davis Lori  <br/><br/>
Checkpoint inhibitor therapy:  Immune-related adverse event management/ 
Lori Davis, Mary Beth Casselbury, Sharon Wilson  
 - Vol. 54 (11) pages 26-34 :  Illustrations:  27 cm 
<br/><br/> Treatment with immune checkpoint inhibitors for cancer is associated with a high prevalence of multiple immune-related toxicities. Immune-related adverse events (irAEs) can occur anytime during treatment and up to 3 months after treatment. This article discusses checkpoint inhibitor therapy and describes the implementation of a patient education program focused on recognizing immunotherapy irAEs and their toxicities. 
<br/><br/><label>ISSN: </label>0360-4039 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Checkpoint inhibitor therapy, immune-related adverse events (irAEs), immune checkpoint inhibitors (ICIs), immunotherapy, oncology